201 related articles for article (PubMed ID: 17067159)
1. Dehydrozingerone, chalcone, and isoeugenol analogues as in vitro anticancer agents.
Tatsuzaki J; Bastow KF; Nakagawa-Goto K; Nakamura S; Itokawa H; Lee KH
J Nat Prod; 2006 Oct; 69(10):1445-9. PubMed ID: 17067159
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of indolyl chalcones as antitumor agents.
Kumar D; Kumar NM; Akamatsu K; Kusaka E; Harada H; Ito T
Bioorg Med Chem Lett; 2010 Jul; 20(13):3916-9. PubMed ID: 20627724
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of novel β-carboline based chalcones with high cytotoxic activity against breast cancer cells.
Chauhan SS; Singh AK; Meena S; Lohani M; Singh A; Arya RK; Cheruvu SH; Sarkar J; Gayen JR; Datta D; Chauhan PM
Bioorg Med Chem Lett; 2014 Jul; 24(13):2820-4. PubMed ID: 24844196
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of novel isoxazolyl chalcones as potential anticancer agents.
Wan M; Xu L; Hua L; Li A; Li S; Lu W; Pang Y; Cao C; Liu X; Jiao P
Bioorg Chem; 2014 Jun; 54():38-43. PubMed ID: 24747188
[TBL] [Abstract][Full Text] [Related]
5. Heterocyclic chalcone analogues as potential anticancer agents.
Sharma V; Kumar V; Kumar P
Anticancer Agents Med Chem; 2013 Mar; 13(3):422-32. PubMed ID: 22721390
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic activity of substituted chalcones in terms of molecular electronic properties.
Kupcewicz B; Jarzęcki AA; Małecka M; Krajewska U; Rozalski M
Bioorg Med Chem Lett; 2014 Sep; 24(17):4260-5. PubMed ID: 25091929
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor agents 255: novel glycyrrhetinic acid-dehydrozingerone conjugates as cytotoxic agents.
Tatsuzaki J; Taniguchi M; Bastow KF; Nakagawa-Goto K; Morris-Natschke SL; Itokawa H; Baba K; Lee KH
Bioorg Med Chem; 2007 Sep; 15(18):6193-9. PubMed ID: 17591444
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of novel α-substituted chalcones with potent anti-cancer activities and ability to overcome multidrug resistance.
Riaz S; Iqbal M; Ullah R; Zahra R; Chotana GA; Faisal A; Saleem RSZ
Bioorg Chem; 2019 Jun; 87():123-135. PubMed ID: 30884306
[TBL] [Abstract][Full Text] [Related]
9. Chalcones with electron-withdrawing and electron-donating substituents: anticancer activity against TRAIL resistant cancer cells, structure-activity relationship analysis and regulation of apoptotic proteins.
Mai CW; Yaeghoobi M; Abd-Rahman N; Kang YB; Pichika MR
Eur J Med Chem; 2014 Apr; 77():378-87. PubMed ID: 24675137
[TBL] [Abstract][Full Text] [Related]
10. Novel multidrug resistance reversal agents.
Berger D; Citarella R; Dutia M; Greenberger L; Hallett W; Paul R; Powell D
J Med Chem; 1999 Jun; 42(12):2145-61. PubMed ID: 10377220
[TBL] [Abstract][Full Text] [Related]
11. Total synthesis and anti-tubulin activity of epi-c3 analogues of cryptophycin-24.
Buck SB; Huff JK; Himes RH; Georg GI
J Med Chem; 2004 Jul; 47(14):3697-9. PubMed ID: 15214797
[TBL] [Abstract][Full Text] [Related]
12. Molecular modeling based synthesis and evaluation of in vitro anticancer activity of indolyl chalcones.
Gaur R; Yadav DK; Kumar S; Darokar MP; Khan F; Bhakuni RS
Curr Top Med Chem; 2015; 15(11):1003-12. PubMed ID: 25860176
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and identification of α-cyano bis(indolyl)chalcones as novel anticancer agents.
Kumar D; Maruthi Kumar N; Tantak MP; Ogura M; Kusaka E; Ito T
Bioorg Med Chem Lett; 2014 Nov; 24(22):5170-4. PubMed ID: 25442306
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of Mannich bases of heterocyclic chalcone analogs as cytotoxic agents.
Reddy MV; Su CR; Chiou WF; Liu YN; Chen RY; Bastow KF; Lee KH; Wu TS
Bioorg Med Chem; 2008 Aug; 16(15):7358-70. PubMed ID: 18602831
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and topoisomerases inhibitory activity of heteroaromatic chalcones.
Jeon KH; Yu HB; Kwak SY; Kwon Y; Na Y
Bioorg Med Chem; 2016 Nov; 24(22):5921-5928. PubMed ID: 27707625
[TBL] [Abstract][Full Text] [Related]
16. Dehydrozingerone and isoeugenol as inhibitors of lipid peroxidation and as free radical scavengers.
Rajakumar DV; Rao MN
Biochem Pharmacol; 1993 Dec; 46(11):2067-72. PubMed ID: 8267655
[TBL] [Abstract][Full Text] [Related]
17. Novel p-Functionalized Chromen-4-on-3-yl Chalcones Bearing Astonishing Boronic Acid Moiety as MDM2 Inhibitor: Synthesis, Cytotoxic Evaluation and Simulation Studies.
Bhatia RK; Singh L; Garg R; Kaur M; Yadav M; Madan J; Kancherla S; Pissurlenkar RRS; Coutinho EC
Med Chem; 2020; 16(2):212-228. PubMed ID: 31146672
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors and promoters of tubulin polymerization: synthesis and biological evaluation of chalcones and related dienones as potential anticancer agents.
Dyrager C; Wickström M; Fridén-Saxin M; Friberg A; Dahlén K; Wallén EA; Gullbo J; Grøtli M; Luthman K
Bioorg Med Chem; 2011 Apr; 19(8):2659-65. PubMed ID: 21459004
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of a novel series of chalcones incorporated pyrazole moiety as anticancer and antimicrobial agents.
Mohamed MF; Mohamed MS; Shouman SA; Fathi MM; Abdelhamid IA
Appl Biochem Biotechnol; 2012 Nov; 168(5):1153-62. PubMed ID: 22948604
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a new dihydroeugenol-chalcone hybrid with cytotoxic and anti-migratory potential: A dual-action hit for cancer therapeutics.
Nakao IA; Almeida TC; Cardoso Reis AC; Coutinho GG; Hermenegildo AM; Cordeiro CF; da Silva GN; Dias DF; Brandão GC; Pinto Braga SF; de Souza TB
Bioorg Med Chem; 2023 Dec; 96():117516. PubMed ID: 37944413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
